Silenor

Insomnia, Neurotic depression, Depression + 8 more

Treatment

20 Active Studies for Silenor

What is Silenor

Doxepin

The Generic name of this drug

Treatment Summary

Doxepin is a medication used to treat depression and anxiety. It belongs to a class of drugs called tricyclic antidepressants, but it does not have the same exact properties as them. Doxepin was first approved by the FDA in 1969 for use as an antidepressant and was later approved in 2010 for the treatment of insomnia. It was developed by Pfizer and is available under the brand name Silenor.

Sinequan

is the brand name

image of different drug pills on a surface

Silenor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sinequan

Doxepin

1969

307

Effectiveness

How Silenor Affects Patients

Doxepin is a type of antidepressant that works by decreasing electrical activity in the brain. It can cause antidepressant, sedative, and anticholinergic effects, but at higher doses the anticholinergic and antiadrenergic properties become more prominent. The antidepressant effects of doxepin become noticeable after 2 weeks, while the sedative effects can be seen right away.

How Silenor works in the body

Doxepin works by blocking histamine receptors, which helps to treat skin conditions. Additionally, it works on the central nervous system to increase the activity of norepinephrine and serotonin, which are neurotransmitters. This increases the activity at the post-synaptic neuron receptor sites. Doxepin also desensitizes serotonin 1A receptors and beta-adrenergic receptors. Lastly, it is thought to increase dopamine activity in the frontal cortex.

When to interrupt dosage

The dosage of Silenor is contingent upon the identified condition, including Depression, Involutional, Mental Disorder, Organic and Insomnia. The measure of dosage is contingent upon the technique of application (e.g. Oral or Tablet - Oral) featured in the table beneath.

Condition

Dosage

Administration

Insomnia

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neurotic depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Generalized Anxiety Disorder

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neuropathic Pain

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Itching

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Behcet Syndrome

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Alcoholism

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Neurodermatitis

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

Silenor Contraindications

Condition

Risk Level

Notes

untreated narrow angle glaucoma

Do Not Combine

Pulse Frequency

Do Not Combine

Urinary Retention

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxepin may interact with Pulse Frequency

There are 20 known major drug interactions with Silenor.

Common Silenor Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.

Acepromazine

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.

Alfuzosin

Major

Doxepin may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Silenor Toxicity & Overdose Risk

Taking too much doxepin can cause seizures, irregular heartbeat, unconsciousness, low blood pressure, and depression of the central nervous system. It can also lead to changes in electrocardiogram results and even death. Additionally, doxepin affects fertility in men and women, leading to decreased implantation and litter size, as well as abnormal sperm and reduced sperm motility. There is no evidence that it causes cancer or genetic mutations.

Silenor Novel Uses: Which Conditions Have a Clinical Trial Featuring Silenor?

Currently, 1020 active studies are looking into the potential of Silenor to provide relief from Generalized Anxiety Disorder, Atopic Dermatitis and Bipolar Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

188 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 3, Phase 1

Depressive Disorder, Major

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Depression

301 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Neurotic depression

0 Actively Recruiting

Depressive Disorder, Major

0 Actively Recruiting

Itching

4 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Neurodermatitis

0 Actively Recruiting

Silenor Reviews: What are patients saying about Silenor?

5

Patient Review

6/15/2016

Silenor for Chronic Trouble Sleeping

I've been using this treatment for two weeks and it's helped me stay asleep through the night. At first I felt groggy during the day, but that has passed. Now I'm really pleased with how well it works.

5

Patient Review

5/12/2016

Silenor for Chronic Trouble Sleeping

This was very easy to use, and it worked immediately.

5

Patient Review

2/22/2018

Silenor for Chronic Trouble Sleeping

I find that if I eat dinner no later than 6:30 PM and then take Silenor at 10:30 PM, I sleep really well. Before taking this medication, I would average 4 to 5 hours of sleep per night; however, now I'm averaging 7.5 hours of sleep per night.

4.7

Patient Review

3/14/2016

Silenor for Chronic Trouble Sleeping

Before taking Silenor, I was only sleeping for two to four hours per night. This medication doesn't make you fall asleep, but it does help you stay asleep once you do fall asleep. It's been a lifesaver.

4.3

Patient Review

9/22/2014

Silenor for Chronic Trouble Sleeping

I've been using Ambien for a while now, and unfortunately my body became used to it after a few years. Thankfully, my doctor recommended that I also take Silenor in order to combat this problem. So far it's working great!

4.3

Patient Review

10/17/2016

Silenor for Chronic Trouble Sleeping

I love how this treatment helps me sleep, but unfortunately I have to be careful not to use it more than a couple nights in a row or else I get a dry mouth.

2.7

Patient Review

4/28/2018

Silenor for Chronic Trouble Sleeping

This drug helped me sleep at first, but after a few weeks I started experiencing some bad side effects. The worst was memory loss; I would constantly forget things or do something and then completely forget about it. It also made my depression and anxiety much worse. Do not take more than prescribed, as I made this mistake and slept for over 24 hours straight. Would not recommend this drug.

2.3

Patient Review

5/9/2015

Silenor for Chronic Trouble Sleeping

I have been taking this medication for a week now and it keeps me up all night. I would not recommend it to anyone.

2.3

Patient Review

8/29/2016

Silenor for Chronic Trouble Sleeping

Unfortunately, this did not help me fall asleep at all. As a result, I've gotten no sleep and feel pretty terrible.

2.3

Patient Review

12/21/2014

Silenor for Chronic Trouble Sleeping

This medication definitely keeps me awake; however, it also gives me weird and intrusive thoughts. Additionally, I feel like the room temperature is significantly warmer than it actually is.

2

Patient Review

7/24/2018

Silenor for Chronic Trouble Sleeping

This drug was sometimes effective when I took it to sleep, but not always. At $25 a bottle, it was worth trying. However, now that the price has gone up to $100 for a 30 day supply, it's not worth it anymore.

1.7

Patient Review

11/6/2016

Silenor for Chronic Trouble Sleeping

I would not recommend this drug to anyone. It caused me severe depression and crying fits, and did nothing to help my insomnia.

1.7

Patient Review

11/1/2015

Silenor for Chronic Trouble Sleeping

Ambien only helped me sleep for four hours, so I decided to try this treatment. The first night, I woke up after only one hour of sleep. The second night, I took two doses and slept for an extra hour... but that still wasn't enough. This didn't work for me at all.

1.7

Patient Review

11/10/2019

Silenor for Chronic Trouble Sleeping

PSA - I was prescribed doxepin for insomnia and anxiety. After a lower dose was not effective, my Dr. increased the dose. The first night on the increased dose, I slept drove and was arrested for a DUI. I also had significant memory issues during the several months I was prescribed doxepin and which have persisted. Upon discontinuing doxepin, side effects ceased. Take with EXTREME CAUTION

1.7

Patient Review

7/24/2018

Silenor for Chronic Trouble Sleeping

I halved the Silenor tablet my doctor prescribed me for insomnia after the first dose made me feel like a zombie the next day. Even halving the dosage leaves me feeling drowsy and barely functional for several hours afterward, so it's not worth it to me.

1

Patient Review

10/15/2016

Silenor for Chronic Trouble Sleeping

This treatment was ineffective for me and made it harder to function the next day. I wouldn't recommend it to anyone with chronic insomnia.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about silenor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does it take for Silenor to kick in?

"After taking doxepin, you should limit your activities to those necessary to prepare for sleep. Doxepin works best when taken 3 hours after a meal and within 30 minutes of bedtime."

Answered by AI

What are the side effects of Silenor?

"trouble sleeping

Drowsiness, dizziness, stuffy nose, sneezing, sore throat, nausea, vomiting, diarrhea, constipation, loss of appetite, and trouble sleeping are all symptoms of the cold."

Answered by AI

Is Silenor a narcotic?

"The manufacturer of Silenor claims that it is a non-abusable option for insomnia relief and is not classified as a controlled substance by the DEA."

Answered by AI

Is Silenor a good sleeping pill?

"Doxepin is a medication used to treat insomnia. It is in a class of medications called tricyclic antidepressants. Doxepin works by slowing activity in the brain to allow sleep."

Answered by AI

Clinical Trials for Silenor

Image of University of California, Los Angeles in Los Angeles, United States.

Digital Therapy for Postpartum Depression

18+
Female
Los Angeles, CA

The purpose of this study is to determine if the addition of digital sensing data collected from phones and watches during the early stages of perinatal depression (PND) treatment can better predict treatment outcomes than using self-reported symptoms alone.STAND for PND: The UCLA Depression Grand Challenge (DGC) has previously developed a technology-assisted, scalable therapy system called STAND (Screening and Treatment for ANxiety and Depression) for perinatal depression (PND) and has demonstrated in an initial randomized clinical trial that this treatment intervention to be as effective as psychiatrist delivered care for PND. In this study, the investigators will administer STAND for PND for up to 12 weeks as part of study participation. There will be no comparison between our treatment intervention and a treatment as usual condition, as this is not a trial of efficacy. In the STAND for PND treatment model, women with moderate symptoms will be routed to coach-guided, digital cognitive behavioral therapy (CBT) tailored to PND, which has been demonstrated to be an effective treatment approach for PND. Women with severe depression or suicidality will be routed to clinician delivered CBT, with pharmacotherapy as needed, with both CBT and pharmacotherapy demonstrated to be effective treatment approaches for PND. Symptoms will be regularly monitored throughout the intervention period. Digital Sensing in Depression: The DGC also has substantial experience in large-scale longitudinal digital sensing studies, and experience identifying associations between self-report or clinical ratings of depressive symptoms and digital sensing features, including in pregnant and postpartum women. Digital Sensing in a STAND for PND study: In our previous STAND for PND study, the investigators did not include digital sensing. In this next phase of our research program, the investigators will collect digital sensing data from phones and watches during the first four weeks of study participation. The investigators will enroll up to 250 women during their last trimester or who are in the postpartum period to participate in the 12-week study, which includes treatment provided through the STAND for PND program of care and during which the investigators will obtain 4-weeks of digital sensing data.The investigators will be testing whether behaviors measures through digital sensing (i.e., digital features) in combination with self-reported depression symptoms will better predict treatment outcomes than the self-reported depression symptoms alone. The investigators are testing the hypothesis that prospective longitudinal assessments using digital devices will enhance our ability to predict outcomes of STAND-PND.This project is part of a larger program of research that aims to improve clinical decision-making for PND by establishing a clinical care model for PND that fully integrates digital sensing with digital therapy. An additional objective of this program of research is to target low-income mothers from populations that have had limited access to mental healthcare, given that this population is particularly vulnerable to the impact of PND.

Waitlist Available
Has No Placebo

University of California, Los Angeles

Nelson Freimer, MD

Image of Imperial Valley College in Imperial, United States.

Cognitive Behavioral Therapy for Mental Health

18+
All Sexes
Imperial, CA

The goal of this study is to understand why certain treatments help people reduce repetitive negative thinking (RNT), which is common in many mental health problems. We want to: 1. Figure out what actually causes repetitive negative thinking to decrease when people use cognitive-behavioral therapy (CBT). 2. Find out which parts of RNT-focused CBT are the most important - the parts that truly make a difference in reducing RNT. The main result we will look at is how much a person's repetitive negative thought patterns change from the start of the study to the end of treatment (16 weeks). We will measure this using the Perseverative Thinking Questionnaire at baseline and week 16.

Waitlist Available
Has No Placebo

Imperial Valley College

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials
Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Waitlist Available
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

Cognitive Training + tDCS for Depression

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking. In this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated. Participants will be randomized to one of three study groups: 1. Depression cognitive training treatment with active brain stimulation 2. Depression cognitive training treatment with sham brain stimulation 3. Non-specific cognitive training treatment with sham brain stimulation The main questions this clinical trial aims to answer are: * Does "depression cognitive training treatment with active brain stimulation" benefit thinking and memory more so than the other treatments? * Does "depression cognitive training treatment with active brain stimulation" benefit brain functioning more so than the other treatments? Participants will: * Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months. * Visit the research center daily for 4 weeks to complete their assigned treatment.

Waitlist Available
Has No Placebo

Vanderbilt University Medical Center

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials
Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of Southern Methodist University in Dallas, United States.

Positive Affect Treatment for Depression and Anxiety

18 - 65
All Sexes
Dallas, TX

The purpose of this study is to evaluate the feasibility and acceptability of Positive Affect Treatment (PAT) in a Spanish-speaking population. PAT is a psychotherapy specifically aimed at enhancing reward sensitivity in individuals with low positive affect (a core feature of anhedonia) in the context of depression or anxiety. Target enrollment is 12 participants with low positive affect and depression or anxiety and impaired functioning, between the ages of 18 and 65 years. Participants will complete psychiatric assessments and self-report questionnaires as part of the study. The total length of participation is around 4 months.

Waitlist Available
Has No Placebo

Southern Methodist University

Alicia E Meuret, Ph.D.

Image of CVT in Centennial, United States.

Treatment for Depression

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials